Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis
- 1 January 2018
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 53 (1) , 105-107
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Horse anti‐thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no‐go?European Journal of Haematology, 2016
- Effects of Immunosuppressive Therapy in a Patient with Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria (AA-PNH) Syndrome during Ongoing Eculizumab TreatmentInternal Medicine, 2014
- Current concepts in the pathophysiology and treatment of aplastic anemiaHematology-American Society Hematology Education Program, 2013
- Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disordersImmunobiology, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single‐lineage marrow failure: a pilot study and a survey from the EBMT WPSAABritish Journal of Haematology, 2010
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategoriesBlood, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006
- Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortalityBlood, 1976